Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency" [Thromb. Res. volume 259 (2026) https://doi.org/10.1016/j.thromres.2026.109616].

Thrombosis research·2026
Same author

Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency.

Thrombosis research·2026
Same author

Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency.

Thrombosis and haemostasis·2025
Same author

Updated Egyptian national guidelines for management of hemophilia A in children & adolescents.

Annals of hematology·2025
Same author

Genetic Correlation of HBB, HFE and HAMP Genes to Endocrinal Complications in Egyptian Beta Thalassemia Major Patients.

Biochemical genetics·2024
Same author

Bringing global hematology research to the forefront.

Blood advances·2024

Related Experiment Video

Updated: Jun 17, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Fetal globin induction in beta-thalassemia.

Amal El-Beshlawy1, Mona Hamdy, Mona El Ghamrawy

  • 1Pediatric Hematology Department, Cairo University Hospital, Cairo, Egypt. amalelbeshlawy@yahoo.com

Hemoglobin
|December 17, 2009
PubMed
Summary

Inducing fetal hemoglobin (HbF) in thalassemia patients offers a promising therapeutic strategy. Natural compounds like resveratrol show potential in boosting HbF, easing anemia, and reducing transfusion dependence.

Area of Science:

  • Hematology
  • Molecular Biology
  • Pharmacology

Background:

  • Thalassemia is characterized by reduced hemoglobin production, leading to anemia.
  • High fetal hemoglobin (HbF) levels correlate with milder thalassemia phenotypes and transfusion independence.
  • Developing strategies to induce HbF is crucial for managing thalassemia, especially in resource-limited settings.

Purpose of the Study:

  • To explore molecules that can induce gamma-globin gene expression and fetal hemoglobin (HbF) production.
  • To identify natural compounds with potential therapeutic benefits for thalassemia patients.

Main Methods:

  • Review of pharmacological agents studied for HbF induction, including erythropoietin, short chain fatty acids, azacytidine, and hydroxycarbamide.
  • Investigation of natural plant-derived compounds, specifically angelicin and resveratrol, as HbF inducers.

More Related Videos

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis
06:40

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Related Experiment Videos

Last Updated: Jun 17, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis
06:40

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Main Results:

  • Certain pharmacological agents have been investigated for their ability to increase HbF.
  • Natural compounds like angelicin and resveratrol demonstrate potent induction of erythroid differentiation and increased HbF in erythroid progenitors.
  • These inducers offer a potential alternative for managing thalassemia.

Conclusions:

  • Induction of HbF is a key therapeutic goal for thalassemia.
  • Natural compounds present a viable and potentially cost-effective approach to increasing HbF levels.
  • Boosting HbF production is vital for improving clinical outcomes in beta-thalassemia patients, particularly in developing countries.